世界の良性前立腺肥大症（BPH）治療市場 2021：企業別、地域別、種類・用途別

• 英文タイトル：Global Benign Prostatic Hyperplasia (BPH) Treatment Market 2021 by Company, Regions, Type and Application, Forecast to 2026

• レポートコード：GIR-107A12085
• 出版社/出版日：GlobalInfoResearch / 2021年7月
※2024年版があります。お問い合わせください。
• レポート形態：英文、PDF、108ページ
• 納品方法：Eメール（納期：2~3日）
• 産業分類：医療

• 販売価格（消費税別）

Single User	￥515,040 (USD3,480)	▷ お問い合わせ
Multi User	￥772,560 (USD5,220)	▷ お問い合わせ
Corporate User	￥1,030,080 (USD6,960)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

レポート概要

当調査資料では、良性前立腺肥大症（BPH）治療のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。良性前立腺肥大症（BPH）治療の種類別市場規模（治療薬、機器）、用途別市場規模（病院、クリニック、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。
・良性前立腺肥大症（BPH）治療の市場概要
・企業情報（企業概要、製品概要、販売量、価格、売上）：Pfizer、Sanofi、GlaxoSmithKline、Boston Scientific、Teleflex、Cardinal Health、Allergan、Teva Pharmaceutical、Mylan、Eli Lilly
・企業別市場シェア
・地域別市場分析2016年-2026年
・種類別分析2016年-2026年：治療薬、機器
・用途別分析2016年-2026年：病院、クリニック、その他
・良性前立腺肥大症（BPH）治療の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ
・良性前立腺肥大症（BPH）治療のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア
・良性前立腺肥大症（BPH）治療のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア
・良性前立腺肥大症（BPH）治療の南米市場規模2016年-2026年：ブラジル、アルゼンチン
・良性前立腺肥大症（BPH）治療の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ
・販売チャネル、流通業者・代理店、顧客リスト
・調査の結果・結論

The Benign Prostatic Hyperplasia (BPH) Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest research, the global Benign Prostatic Hyperplasia (BPH) Treatment size is estimated to be USD xx million in 2026 from USD xx million in 2020, with a change XX% between 2020 and 2021. The global Benign Prostatic Hyperplasia (BPH) Treatment market size is expected to grow at a CAGR of xx% for the next five years.

Market segmentation
Benign Prostatic Hyperplasia (BPH) Treatment market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers
Drugs
Devices

Market segment by Application, can be divided into
Hospitals
Clinics
Others

Market segment by players, this report covers
Pfizer
Sanofi
GlaxoSmithKline
Boston Scientific
Teleflex
Cardinal Health
Allergan
Teva Pharmaceutical
Mylan
Eli Lilly

Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

レポート目次

1 Market Overview
1.1 Product Overview and Scope of Benign Prostatic Hyperplasia (BPH) Treatment
1.2 Classification of Benign Prostatic Hyperplasia (BPH) Treatment by Type
1.2.1 Overview: Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global Benign Prostatic Hyperplasia (BPH) Treatment Revenue Market Share by Type in 2020
1.2.3 Drugs
1.2.4 Devices
1.3 Global Benign Prostatic Hyperplasia (BPH) Treatment Market by Application
1.3.1 Overview: Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size & Forecast
1.5 Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size and Forecast by Region
1.5.1 Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Region, (2016-2021)
1.5.3 North America Benign Prostatic Hyperplasia (BPH) Treatment Market Size and Prospect (2016-2026)
1.5.4 Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Treatment Market Size and Prospect (2016-2026)
1.5.6 South America Benign Prostatic Hyperplasia (BPH) Treatment Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Treatment Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 Benign Prostatic Hyperplasia (BPH) Treatment Market Drivers
1.6.2 Benign Prostatic Hyperplasia (BPH) Treatment Market Restraints
1.6.3 Benign Prostatic Hyperplasia (BPH) Treatment Trends Analysis
2 Company Profiles
2.1 Pfizer
2.1.1 Pfizer Details
2.1.2 Pfizer Major Business
2.1.3 Pfizer Benign Prostatic Hyperplasia (BPH) Treatment Product and Solutions
2.1.4 Pfizer Benign Prostatic Hyperplasia (BPH) Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 Pfizer Recent Developments and Future Plans
2.2 Sanofi
2.2.1 Sanofi Details
2.2.2 Sanofi Major Business
2.2.3 Sanofi Benign Prostatic Hyperplasia (BPH) Treatment Product and Solutions
2.2.4 Sanofi Benign Prostatic Hyperplasia (BPH) Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 Sanofi Recent Developments and Future Plans
2.3 GlaxoSmithKline
2.3.1 GlaxoSmithKline Details
2.3.2 GlaxoSmithKline Major Business
2.3.3 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Treatment Product and Solutions
2.3.4 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 GlaxoSmithKline Recent Developments and Future Plans
2.4 Boston Scientific
2.4.1 Boston Scientific Details
2.4.2 Boston Scientific Major Business
2.4.3 Boston Scientific Benign Prostatic Hyperplasia (BPH) Treatment Product and Solutions
2.4.4 Boston Scientific Benign Prostatic Hyperplasia (BPH) Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 Boston Scientific Recent Developments and Future Plans
2.5 Teleflex
2.5.1 Teleflex Details
2.5.2 Teleflex Major Business
2.5.3 Teleflex Benign Prostatic Hyperplasia (BPH) Treatment Product and Solutions
2.5.4 Teleflex Benign Prostatic Hyperplasia (BPH) Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 Teleflex Recent Developments and Future Plans
2.6 Cardinal Health
2.6.1 Cardinal Health Details
2.6.2 Cardinal Health Major Business
2.6.3 Cardinal Health Benign Prostatic Hyperplasia (BPH) Treatment Product and Solutions
2.6.4 Cardinal Health Benign Prostatic Hyperplasia (BPH) Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.6.5 Cardinal Health Recent Developments and Future Plans
2.7 Allergan
2.7.1 Allergan Details
2.7.2 Allergan Major Business
2.7.3 Allergan Benign Prostatic Hyperplasia (BPH) Treatment Product and Solutions
2.7.4 Allergan Benign Prostatic Hyperplasia (BPH) Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.7.5 Allergan Recent Developments and Future Plans
2.8 Teva Pharmaceutical
2.8.1 Teva Pharmaceutical Details
2.8.2 Teva Pharmaceutical Major Business
2.8.3 Teva Pharmaceutical Benign Prostatic Hyperplasia (BPH) Treatment Product and Solutions
2.8.4 Teva Pharmaceutical Benign Prostatic Hyperplasia (BPH) Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.8.5 Teva Pharmaceutical Recent Developments and Future Plans
2.9 Mylan
2.9.1 Mylan Details
2.9.2 Mylan Major Business
2.9.3 Mylan Benign Prostatic Hyperplasia (BPH) Treatment Product and Solutions
2.9.4 Mylan Benign Prostatic Hyperplasia (BPH) Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.9.5 Mylan Recent Developments and Future Plans
2.10 Eli Lilly
2.10.1 Eli Lilly Details
2.10.2 Eli Lilly Major Business
2.10.3 Eli Lilly Benign Prostatic Hyperplasia (BPH) Treatment Product and Solutions
2.10.4 Eli Lilly Benign Prostatic Hyperplasia (BPH) Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.10.5 Eli Lilly Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Benign Prostatic Hyperplasia (BPH) Treatment Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 3 Benign Prostatic Hyperplasia (BPH) Treatment Players Market Share
3.2.2 Top 10 Benign Prostatic Hyperplasia (BPH) Treatment Players Market Share
3.2.3 Market Competition Trend
3.3 Benign Prostatic Hyperplasia (BPH) Treatment Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Benign Prostatic Hyperplasia (BPH) Treatment Revenue and Market Share by Type (2016-2021)
4.2 Global Benign Prostatic Hyperplasia (BPH) Treatment Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global Benign Prostatic Hyperplasia (BPH) Treatment Revenue Market Share by Application (2016-2021)
5.2 Benign Prostatic Hyperplasia (BPH) Treatment Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America Benign Prostatic Hyperplasia (BPH) Treatment Revenue by Type (2016-2026)
6.2 North America Benign Prostatic Hyperplasia (BPH) Treatment Revenue by Application (2016-2026)
6.3 North America Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Country
6.3.1 North America Benign Prostatic Hyperplasia (BPH) Treatment Revenue by Country (2016-2026)
6.3.2 United States Benign Prostatic Hyperplasia (BPH) Treatment Market Size and Forecast (2016-2026)
6.3.3 Canada Benign Prostatic Hyperplasia (BPH) Treatment Market Size and Forecast (2016-2026)
6.3.4 Mexico Benign Prostatic Hyperplasia (BPH) Treatment Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe Benign Prostatic Hyperplasia (BPH) Treatment Revenue by Type (2016-2026)
7.2 Europe Benign Prostatic Hyperplasia (BPH) Treatment Revenue by Application (2016-2026)
7.3 Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Country
7.3.1 Europe Benign Prostatic Hyperplasia (BPH) Treatment Revenue by Country (2016-2026)
7.3.2 Germany Benign Prostatic Hyperplasia (BPH) Treatment Market Size and Forecast (2016-2026)
7.3.3 France Benign Prostatic Hyperplasia (BPH) Treatment Market Size and Forecast (2016-2026)
7.3.4 United Kingdom Benign Prostatic Hyperplasia (BPH) Treatment Market Size and Forecast (2016-2026)
7.3.5 Russia Benign Prostatic Hyperplasia (BPH) Treatment Market Size and Forecast (2016-2026)
7.3.6 Italy Benign Prostatic Hyperplasia (BPH) Treatment Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Treatment Revenue by Type (2016-2026)
8.2 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Treatment Revenue by Application (2016-2026)
8.3 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Region
8.3.1 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Treatment Revenue by Region (2016-2026)
8.3.2 China Benign Prostatic Hyperplasia (BPH) Treatment Market Size and Forecast (2016-2026)
8.3.3 Japan Benign Prostatic Hyperplasia (BPH) Treatment Market Size and Forecast (2016-2026)
8.3.4 South Korea Benign Prostatic Hyperplasia (BPH) Treatment Market Size and Forecast (2016-2026)
8.3.5 India Benign Prostatic Hyperplasia (BPH) Treatment Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia Benign Prostatic Hyperplasia (BPH) Treatment Market Size and Forecast (2016-2026)
8.3.7 Australia Benign Prostatic Hyperplasia (BPH) Treatment Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America Benign Prostatic Hyperplasia (BPH) Treatment Revenue by Type (2016-2026)
9.2 South America Benign Prostatic Hyperplasia (BPH) Treatment Revenue by Application (2016-2026)
9.3 South America Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Country
9.3.1 South America Benign Prostatic Hyperplasia (BPH) Treatment Revenue by Country (2016-2026)
9.3.2 Brazil Benign Prostatic Hyperplasia (BPH) Treatment Market Size and Forecast (2016-2026)
9.3.3 Argentina Benign Prostatic Hyperplasia (BPH) Treatment Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Treatment Revenue by Type (2016-2026)
10.2 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Treatment Revenue by Application (2016-2026)
10.3 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Country
10.3.1 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Treatment Revenue by Country (2016-2026)
10.3.2 Turkey Benign Prostatic Hyperplasia (BPH) Treatment Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia Benign Prostatic Hyperplasia (BPH) Treatment Market Size and Forecast (2016-2026)
10.3.4 UAE Benign Prostatic Hyperplasia (BPH) Treatment Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer

List of Tables
Table 1. Global Benign Prostatic Hyperplasia (BPH) Treatment Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
Table 2. Global Benign Prostatic Hyperplasia (BPH) Treatment Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
Table 3. Global Market Benign Prostatic Hyperplasia (BPH) Treatment Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
Table 4. Global Benign Prostatic Hyperplasia (BPH) Treatment Revenue (USD Million) by Region (2016-2021)
Table 5. Global Benign Prostatic Hyperplasia (BPH) Treatment Revenue Market Share by Region (2021-2026)
Table 6. Pfizer Corporate Information, Head Office, and Major Competitors
Table 7. Pfizer Major Business
Table 8. Pfizer Benign Prostatic Hyperplasia (BPH) Treatment Product and Solutions
Table 9. Pfizer Benign Prostatic Hyperplasia (BPH) Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 10. Sanofi Corporate Information, Head Office, and Major Competitors
Table 11. Sanofi Major Business
Table 12. Sanofi Benign Prostatic Hyperplasia (BPH) Treatment Product and Solutions
Table 13. Sanofi Benign Prostatic Hyperplasia (BPH) Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 14. GlaxoSmithKline Corporate Information, Head Office, and Major Competitors
Table 15. GlaxoSmithKline Major Business
Table 16. GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Treatment Product and Solutions
Table 17. GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 18. Boston Scientific Corporate Information, Head Office, and Major Competitors
Table 19. Boston Scientific Major Business
Table 20. Boston Scientific Benign Prostatic Hyperplasia (BPH) Treatment Product and Solutions
Table 21. Boston Scientific Benign Prostatic Hyperplasia (BPH) Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 22. Teleflex Corporate Information, Head Office, and Major Competitors
Table 23. Teleflex Major Business
Table 24. Teleflex Benign Prostatic Hyperplasia (BPH) Treatment Product and Solutions
Table 25. Teleflex Benign Prostatic Hyperplasia (BPH) Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 26. Cardinal Health Corporate Information, Head Office, and Major Competitors
Table 27. Cardinal Health Major Business
Table 28. Cardinal Health Benign Prostatic Hyperplasia (BPH) Treatment Product and Solutions
Table 29. Cardinal Health Benign Prostatic Hyperplasia (BPH) Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 30. Allergan Corporate Information, Head Office, and Major Competitors
Table 31. Allergan Major Business
Table 32. Allergan Benign Prostatic Hyperplasia (BPH) Treatment Product and Solutions
Table 33. Allergan Benign Prostatic Hyperplasia (BPH) Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 34. Teva Pharmaceutical Corporate Information, Head Office, and Major Competitors
Table 35. Teva Pharmaceutical Major Business
Table 36. Teva Pharmaceutical Benign Prostatic Hyperplasia (BPH) Treatment Product and Solutions
Table 37. Teva Pharmaceutical Benign Prostatic Hyperplasia (BPH) Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 38. Mylan Corporate Information, Head Office, and Major Competitors
Table 39. Mylan Major Business
Table 40. Mylan Benign Prostatic Hyperplasia (BPH) Treatment Product and Solutions
Table 41. Mylan Benign Prostatic Hyperplasia (BPH) Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 42. Eli Lilly Corporate Information, Head Office, and Major Competitors
Table 43. Eli Lilly Major Business
Table 44. Eli Lilly Benign Prostatic Hyperplasia (BPH) Treatment Product and Solutions
Table 45. Eli Lilly Benign Prostatic Hyperplasia (BPH) Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 46. Global Benign Prostatic Hyperplasia (BPH) Treatment Revenue (USD Million) by Players (2019-2021)
Table 47. Global Benign Prostatic Hyperplasia (BPH) Treatment Revenue Share by Players (2019-2021)
Table 48. Breakdown of Benign Prostatic Hyperplasia (BPH) Treatment by Company Type (Tier 1, Tier 2 and Tier 3)
Table 49. Benign Prostatic Hyperplasia (BPH) Treatment Players Head Office, Products and Services Provided
Table 50. Benign Prostatic Hyperplasia (BPH) Treatment Mergers & Acquisitions in the Past Five Years
Table 51. Benign Prostatic Hyperplasia (BPH) Treatment New Entrants and Expansion Plans
Table 52. Global Benign Prostatic Hyperplasia (BPH) Treatment Revenue (USD Million) by Type (2016-2021)
Table 53. Global Benign Prostatic Hyperplasia (BPH) Treatment Revenue Share by Type (2016-2021)
Table 54. Global Benign Prostatic Hyperplasia (BPH) Treatment Revenue Forecast by Type (2021-2026)
Table 55. Global Benign Prostatic Hyperplasia (BPH) Treatment Revenue by Application (2016-2021)
Table 56. Global Benign Prostatic Hyperplasia (BPH) Treatment Revenue Forecast by Application (2021-2026)
Table 57. North America Benign Prostatic Hyperplasia (BPH) Treatment Revenue by Type (2016-2021) & (USD Million)
Table 58. North America Benign Prostatic Hyperplasia (BPH) Treatment Revenue by Type (2021-2026) & (USD Million)
Table 59. North America Benign Prostatic Hyperplasia (BPH) Treatment Revenue by Application (2016-2021) & (USD Million)
Table 60. North America Benign Prostatic Hyperplasia (BPH) Treatment Revenue by Application (2021-2026) & (USD Million)
Table 61. North America Benign Prostatic Hyperplasia (BPH) Treatment Revenue by Country (2016-2021) & (USD Million)
Table 62. North America Benign Prostatic Hyperplasia (BPH) Treatment Revenue by Country (2021-2026) & (USD Million)
Table 63. Europe Benign Prostatic Hyperplasia (BPH) Treatment Revenue by Type (2016-2021) & (USD Million)
Table 64. Europe Benign Prostatic Hyperplasia (BPH) Treatment Revenue by Type (2021-2026) & (USD Million)
Table 65. Europe Benign Prostatic Hyperplasia (BPH) Treatment Revenue by Application (2016-2021) & (USD Million)
Table 66. Europe Benign Prostatic Hyperplasia (BPH) Treatment Revenue by Application (2021-2026) & (USD Million)
Table 67. Europe Benign Prostatic Hyperplasia (BPH) Treatment Revenue by Country (2016-2021) & (USD Million)
Table 68. Europe Benign Prostatic Hyperplasia (BPH) Treatment Revenue by Country (2021-2026) & (USD Million)
Table 69. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Treatment Revenue by Type (2016-2021) & (USD Million)
Table 70. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Treatment Revenue by Type (2021-2026) & (USD Million)
Table 71. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Treatment Revenue by Application (2016-2021) & (USD Million)
Table 72. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Treatment Revenue by Application (2021-2026) & (USD Million)
Table 73. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Treatment Revenue by Region (2016-2021) & (USD Million)
Table 74. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Treatment Revenue by Region (2021-2026) & (USD Million)
Table 75. South America Benign Prostatic Hyperplasia (BPH) Treatment Revenue by Type (2016-2021) & (USD Million)
Table 76. South America Benign Prostatic Hyperplasia (BPH) Treatment Revenue by Type (2021-2026) & (USD Million)
Table 77. South America Benign Prostatic Hyperplasia (BPH) Treatment Revenue by Application (2016-2021) & (USD Million)
Table 78. South America Benign Prostatic Hyperplasia (BPH) Treatment Revenue by Application (2021-2026) & (USD Million)
Table 79. South America Benign Prostatic Hyperplasia (BPH) Treatment Revenue by Country (2016-2021) & (USD Million)
Table 80. South America Benign Prostatic Hyperplasia (BPH) Treatment Revenue by Country (2021-2026) & (USD Million)
Table 81. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Treatment Revenue by Type (2016-2021) & (USD Million)
Table 82. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Treatment Revenue by Type (2021-2026) & (USD Million)
Table 83. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Treatment Revenue by Application (2016-2021) & (USD Million)
Table 84. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Treatment Revenue by Application (2021-2026) & (USD Million)
Table 85. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Treatment Revenue by Country (2016-2021) & (USD Million)
Table 86. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Treatment Revenue by Country (2021-2026) & (USD Million)
List of Figures
Figure 1. Benign Prostatic Hyperplasia (BPH) Treatment Picture
Figure 2. Global Benign Prostatic Hyperplasia (BPH) Treatment Revenue Market Share by Type in 2020
Figure 3. Drugs
Figure 4. Devices
Figure 5. Benign Prostatic Hyperplasia (BPH) Treatment Revenue Market Share by Application in 2020
Figure 6. Hospitals Picture
Figure 7. Clinics Picture
Figure 8. Others Picture
Figure 9. Global Benign Prostatic Hyperplasia (BPH) Treatment Revenue, (USD Million): 2020 VS 2021 VS 2026
Figure 10. Global Benign Prostatic Hyperplasia (BPH) Treatment Revenue and Forecast (2016-2026) & (USD Million)
Figure 11. Global Benign Prostatic Hyperplasia (BPH) Treatment Revenue Market Share by Region (2016-2026)
Figure 12. Global Benign Prostatic Hyperplasia (BPH) Treatment Revenue Market Share by Region in 2020
Figure 13. North America Benign Prostatic Hyperplasia (BPH) Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 14. Europe Benign Prostatic Hyperplasia (BPH) Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 15. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 16. South America Benign Prostatic Hyperplasia (BPH) Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 17. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 18. Benign Prostatic Hyperplasia (BPH) Treatment Market Drivers
Figure 19. Benign Prostatic Hyperplasia (BPH) Treatment Market Restraints
Figure 20. Benign Prostatic Hyperplasia (BPH) Treatment Market Trends
Figure 21. Pfizer Recent Developments and Future Plans
Figure 22. Sanofi Recent Developments and Future Plans
Figure 23. GlaxoSmithKline Recent Developments and Future Plans
Figure 24. Boston Scientific Recent Developments and Future Plans
Figure 25. Teleflex Recent Developments and Future Plans
Figure 26. Cardinal Health Recent Developments and Future Plans
Figure 27. Allergan Recent Developments and Future Plans
Figure 28. Teva Pharmaceutical Recent Developments and Future Plans
Figure 29. Mylan Recent Developments and Future Plans
Figure 30. Eli Lilly Recent Developments and Future Plans
Figure 31. Global Benign Prostatic Hyperplasia (BPH) Treatment Revenue Share by Players in 2020
Figure 32. Benign Prostatic Hyperplasia (BPH) Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 33. Global Top 3 Players Benign Prostatic Hyperplasia (BPH) Treatment Revenue Market Share in 2020
Figure 34. Global Top 10 Players Benign Prostatic Hyperplasia (BPH) Treatment Revenue Market Share in 2020
Figure 35. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
Figure 36. Global Benign Prostatic Hyperplasia (BPH) Treatment Revenue Share by Type in 2020
Figure 37. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Share Forecast by Type (2021-2026)
Figure 38. Global Benign Prostatic Hyperplasia (BPH) Treatment Revenue Share by Application in 2020
Figure 39. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Share Forecast by Application (2021-2026)
Figure 40. North America Benign Prostatic Hyperplasia (BPH) Treatment Sales Market Share by Type (2016-2026)
Figure 41. North America Benign Prostatic Hyperplasia (BPH) Treatment Sales Market Share by Application (2016-2026)
Figure 42. North America Benign Prostatic Hyperplasia (BPH) Treatment Revenue Market Share by Country (2016-2026)
Figure 43. United States Benign Prostatic Hyperplasia (BPH) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 44. Canada Benign Prostatic Hyperplasia (BPH) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 45. Mexico Benign Prostatic Hyperplasia (BPH) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 46. Europe Benign Prostatic Hyperplasia (BPH) Treatment Sales Market Share by Type (2016-2026)
Figure 47. Europe Benign Prostatic Hyperplasia (BPH) Treatment Sales Market Share by Application (2016-2026)
Figure 48. Europe Benign Prostatic Hyperplasia (BPH) Treatment Revenue Market Share by Country (2016-2026)
Figure 49. Germany Benign Prostatic Hyperplasia (BPH) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 50. France Benign Prostatic Hyperplasia (BPH) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 51. United Kingdom Benign Prostatic Hyperplasia (BPH) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 52. Russia Benign Prostatic Hyperplasia (BPH) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 53. Italy Benign Prostatic Hyperplasia (BPH) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 54. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Treatment Sales Market Share by Type (2016-2026)
Figure 55. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Treatment Sales Market Share by Application (2016-2026)
Figure 56. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Treatment Revenue Market Share by Region (2016-2026)
Figure 57. China Benign Prostatic Hyperplasia (BPH) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 58. Japan Benign Prostatic Hyperplasia (BPH) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 59. South Korea Benign Prostatic Hyperplasia (BPH) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 60. India Benign Prostatic Hyperplasia (BPH) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 61. Southeast Asia Benign Prostatic Hyperplasia (BPH) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 62. Australia Benign Prostatic Hyperplasia (BPH) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 63. South America Benign Prostatic Hyperplasia (BPH) Treatment Sales Market Share by Type (2016-2026)
Figure 64. South America Benign Prostatic Hyperplasia (BPH) Treatment Sales Market Share by Application (2016-2026)
Figure 65. South America Benign Prostatic Hyperplasia (BPH) Treatment Revenue Market Share by Country (2016-2026)
Figure 66. Brazil Benign Prostatic Hyperplasia (BPH) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 67. Argentina Benign Prostatic Hyperplasia (BPH) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 68. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Treatment Sales Market Share by Type (2016-2026)
Figure 69. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Treatment Sales Market Share by Application (2016-2026)
Figure 70. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Treatment Revenue Market Share by Country (2016-2026)
Figure 71. Turkey Benign Prostatic Hyperplasia (BPH) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 72. Saudi Arabia Benign Prostatic Hyperplasia (BPH) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 73. UAE Benign Prostatic Hyperplasia (BPH) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 74. Methodology
Figure 75. Research Process and Data Source

Global Metachromatic Leukodystrophy (MLD) Treatment Market 2021 by Manufacturers, Regions, Type and Application, Forecast to 2026
GIR-107A14479 2021年7月 87Pages
当調査資料では、異染性白質ジストロフィー（MLD）治療のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。異染性白質ジストロフィー（MLD）治療の種類別市場規模（AGT-183、DUOC-01、GSK-2696274、その他）、用途別市場規模（病院、クリニ...

世界の原始神経外胚葉性腫瘍（PNET）治療市場 2021：企業別、地域別、種類・用途別

Global Primitive Neuroectodermal Tumors (PNET) Treatment Market 2021 by Company, Regions, Type and Application, Forecast to 2026
GIR-107A12616 2021年7月 107Pages
当調査資料では、原始神経外胚葉性腫瘍（PNET）治療のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。原始神経外胚葉性腫瘍（PNET）治療の種類別市場規模（外科手術、化学療法、放射線療法）、用途別市場規模（病院、外来手術センター、その他）、地域別市場規模...

世界の慢性閉塞性肺疾患（COPD）治療市場 2021：企業別、地域別、種類・用途別

Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market 2021 by Company, Regions, Type and Application, Forecast to 2026
GIR-107A12165 2021年7月 103Pages
当調査資料では、慢性閉塞性肺疾患（COPD）治療のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。慢性閉塞性肺疾患（COPD）治療の種類別市場規模（コルチコステロイド、ホスホジエステラーゼ4型阻害剤、気管支拡張剤、その他）、用途別市場規模（病院、クリニッ...

世界の結核診断・治療市場 2021：企業別、地域別、種類・用途別

Global Tuberculosis Diagnostics and Treatment Market 2021 by Company, Regions, Type and Application, Forecast to 2026
GIR-107A08969 2021年7月 120Pages
当調査資料では、結核診断・治療のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。結核診断・治療の種類別市場規模（皮膚検査、実験室検査）、用途別市場規模（病院、クリニック、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア...

世界のIBD（潰瘍性大腸炎＆クローン病）治療市場 2021：企業別、地域別、種類・用途別

Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market 2021 by Manufacturers, Regions, Type and Application, Forecast to 2026
GIR-105X09116 2021年5月 104Pages
当調査資料では、IBD（潰瘍性大腸炎＆クローン病）治療のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。IBD（潰瘍性大腸炎＆クローン病）治療の種類別市場規模（TNF阻害剤、アミノサリチル酸、インテグリン拮抗薬、コルチコステロイド）、用途別市場規模（病院...

世界の前立腺動脈塞栓術市場 2021：企業別、地域別、種類・用途別

Global Prostatic Artery Embolization Market 2021 by Manufacturers, Regions, Type and Application, Forecast to 2026
GIR-105X13786 2021年5月 108Pages
当調査資料では、前立腺動脈塞栓術のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。前立腺動脈塞栓術の種類別市場規模（タイプ1、タイプ2）、用途別市場規模（60歳以下、60-85歳、85歳以上）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日...

世界の睡眠時無呼吸診断・治療市場 2021：企業別、地域別、種類・用途別

Global Sleep Apnea Diagnostics and Therapeutics Market 2021 by Company, Regions, Type and Application, Forecast to 2026
GIR-107A11899 2021年7月 81Pages
当調査資料では、睡眠時無呼吸診断・治療のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。睡眠時無呼吸診断・治療の種類別市場規模（睡眠ポリグラフ（PSG）デバイス、アクチグラフシステム、呼吸ポリグラフ、パルスオキシメータ、その他）、用途別市場規模（製薬会社...

世界の良性再発肝内胆汁うっ滞（BRIC）画像診断装置市場 2021：企業別、地域別、種類・用途別

Global Benign Recurrent Intrahepatic Cholestasis (BRIC) Diagnostic Imaging Equipment Market 2021 by Manufacturers, Regions, Type and Application, Forecast to 2026
GIR-105X02373 2021年5月 103Pages
当調査資料では、良性再発肝内胆汁うっ滞（BRIC）画像診断装置のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。良性再発肝内胆汁うっ滞（BRIC）画像診断装置の種類別市場規模（X線、MRI、CT、核イメージング）、用途別市場規模（病院、画像センター）、地...

世界の軟骨無形成症治療市場 2021：企業別、地域別、種類・用途別

Global Achondroplasia Treatment Market 2021 by Company, Regions, Type and Application, Forecast to 2026
GIR-107A12020 2021年7月 74Pages
当調査資料では、軟骨無形成症治療のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。軟骨無形成症治療の種類別市場規模（RBM-007、TA-46、B-701、その他）、用途別市場規模（病院、クリニック、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、...

世界の髄膜炎菌感染症治療市場 2021：企業別、地域別、種類・用途別

Global Meningococcal Infections Treatment Market 2021 by Company, Regions, Type and Application, Forecast to 2026
GIR-107A12464 2021年7月 102Pages
当調査資料では、髄膜炎菌感染症治療のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。髄膜炎菌感染症治療の種類別市場規模（抗生物質、糖質コルチコイド、プロテインC濃縮物）、用途別市場規模（病院、クリニック、その他）、地域別市場規模（北米、アメリカ、ヨーロッ...

世界の前立腺動脈塞栓術市場 2021：企業別、地域別、種類・用途別 The Prostatic Artery Embolization market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade r…
世界の良性再発肝内胆汁うっ滞（BRIC）画像診断装置市場 2021：企業別、地域別、種類・用途別 The Benign Recurrent Intrahepatic Cholestasis (BRIC) Diagnostic Imaging Equipment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global m…
世界の白血病治療薬市場 2021：企業別、地域別、種類・用途別 The Leukemia Treatment Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regula…
世界のペットアレルギー治療薬市場 2021：企業別、地域別、種類・用途別 The Pet Allergy Treatment Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade reg…
世界の軟骨無形成症治療市場 2021：企業別、地域別、種類・用途別 The Achondroplasia Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regula…